Strategy Uses Bitcoin Sales Table for Debt Buybacks
Strategy unveiled a plan to repurchase roughly $1.5 billion of its 2029 notes, with funding options including Bitcoin...
Which Cash Rewards Credit Cards Have No Fees
Learn which cash rewards credit cards have no fees, allowing you to earn rewards without the financial burden. Make informed choices.
27,645 articles
Florence Steakhouse Reopened After Five Years, Then Turmoil
A Florence steakhouse reopened after five years closed, then a viral TikTok critique reshaped its fate. This personal...
Nio Touts First Adjusted Profit: What It Signals Now
Nio is signaling a major profitability milestone with its first adjusted profit, but the real impact for investors de...
Autozone Stock Sank: Unpacking the May Slide and Buyer Risk
AutoZone faced a sharp May drop after mixed results and rising costs. This guide breaks down the drivers, what they m...
Disc Medicine Sells $720k: CFO Moves After FDA Rejection
A biotech insider trade draws attention after an FDA setback. This article unpacks the CFO's $720k stock sale at Disc...
Crocs Stock After Recent Upgrade: Is It a Buy Now?
Analysts just boosted Crocs stock after recent upgrade rumors and data. This guide breaks down why the upgrade happen...
Why Broadcom Stock Sank Today: What Investors Should Know
Broadcom’s latest price move came on the back of a price-target cut and AI optimism colliding with caution. This guid...
Here's Wouldn't Touch This: Why I Won't Invest Now in EVTOL Darling
The eVTOL craze mixes hype with real engineering, regulatory hurdles, and capital burn. Here's why I wouldn't touch t...
Lockheed Stock 2026 Rally Real: Earnings Drive Surge
Lockheed Martin has surged in 2026, led by a robust backlog and growing cash flow that underpin a genuine stock 2026 ...
Morgan Adds Favorite Dividend Stock on July Focus List
J.P. Morgan updates its U.S. Analyst Focus List for July, spotlighting a dependable dividend payer. The move comes as...
Iovance Biotherapeutics: High-Risk Cancer Stock Potential
A bold, high‑risk biotech bet can pay off with patience and discipline. This article breaks down iovance biotherapeut...
At $32, Dream Finders-Beazer Risk Doubles in Rating Drama
Dream Finders has offered cash to acquire Beazer at roughly $32 per share, elevating the stakes for both companies. T...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status